What's new

Orphan designation: povetacicept Treatment of primary IgA nephropathy, 25/03/2025 Positive

Orphan designation: povetacicept Treatment of primary IgA nephropathy, 25/03/2025 Positive

Apr 7, 2025 - 10:47
 0
Orphan designation: povetacicept Treatment of primary IgA nephropathy, 25/03/2025 Positive
Orphan designation: povetacicept Treatment of primary IgA nephropathy, 25/03/2025 Positive
Read More

Tags:

Previous Article

Lilly files lawsuit against home town spa for selling repackaged Zepbound

Next Article

Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on pe...

Related Posts

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 17 December 2025, 10:00 (CET) to 17 December 2025, 12:00 (CET)

Meeting of the Executive Steering Group on Shortages an...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 28, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, Indacaterol (acetate),Mometasone (furoate) (QVM149),Glycopyrronium bromide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0493/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025  0